Vicore Pharma AB
Clinical trials sponsored by Vicore Pharma AB, explained in plain language.
Now part of
Vicore Pharma Holding AB
VICO
NASDAQ STOCKHOLM
A Swedish biotech company developing treatments for respiratory diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for lung scarring: buloxibutid trial underway Results expected May 2027 (estimated)